394
Participants
Start Date
January 1, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
Tranilast
Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
Dexamethasone
Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
Hangzhou Third People's Hospital, Hangzhou
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Shaoxing Central Hospital, Shaoxing
The Third People's Hospital of Hangzhou
OTHER
Xiangya Hospital of Central South University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER